FDA Expands Indication of Pfizer's Besponsa to Include Pediatric Patients with B-cell Precursor Acute Lymphoblastic Leukemia

Besponsa (inotuzumab ozogamicin) was initially approved in August 2017 for adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.

Source link
#FDA #Expands #Indication #Pfizer039s #Besponsa #Include #Pediatric #Patients #Bcell #Precursor #Acute #Lymphoblastic #Leukemia